Forbion has raised $2.6 billion in a fund close the firm calls its largest to date, according to STAT. The figure sets a high-water mark among recently disclosed biotech-only fund closes.

The fund size lands against compressed public biotech valuations and a thinned list of crossover investors, a backdrop that has already pushed several late-stage developers to scale back programs or, in at least one case, shut down entirely. STAT did not disclose the new vehicle's vintage, LP composition, or allocation strategy in the version of the story available outside the paywall.

What does a $2.6 billion fund signal for R&D-stage biotech?

Funds of this size historically allow managers to underwrite both early and late-stage rounds from a single vehicle. For R&D managers building capital plans through 2027, a closed fund at this scale lowers the probability of a Series A or B funding gap in the near term — though the deployment pace and stage tilt will determine the practical effect on individual founders.

Where does Cerevance's Parkinson's program stand?

Privately held Cerevance announced that solengepras, a once-daily oral therapy, met its primary endpoint in the Phase 3 ARISE trial, reducing Parkinson's patients' daily "off" time alongside motor and non-motor symptoms. The company said it will now engage regulators about a potential approval filing.

Cerevance positions solengepras as a Parkinson's treatment that does not act directly on dopamine, which the company argues could spare patients certain side effects of standard dopaminergic therapy. The release omitted the off-time reduction, sample size, and statistical method, leaving magnitude to be scrutinised at upcoming congresses.

Who won the 2026 chemistry Nobel?

The Royal Swedish Academy of Sciences awarded the 2026 Nobel Prize in chemistry to Henri B. Kagan and Kenso Soai for their work on "mirror image" molecules — chiral compounds whose two forms interact differently with biological targets.

The committee cited the laureates' contributions to the controlled synthesis of single-enantiomer compounds, a method drug developers use to manufacture more precise and safer therapeutics. The award formalises a body of work industrially deployed for three decades across small-molecule manufacturing.

Why is Caribou Biosciences shutting down?

Caribou Biosciences, the Doudna-founded cell therapy developer, is closing after failing to raise enough capital to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma. The company could not secure the late-stage private placement or crossover participation needed to advance the program.

The wind-down removes one of a small group of developers pursuing off-the-shelf CAR-T products for B-cell lymphomas, a category that has faced manufacturing scale-up costs and slower hospital adoption than the autologous predecessors already in routine clinical use. Caribou's pipeline beyond the lymphoma program was not addressed in STAT's report.

The morning's items — a record fund close, a Phase 3 readout, a Nobel award, and a public shutdown — capture the two-track structure of the 2026 biotech market: capital remains available for de-risked assets, while platform companies without near-term clinical catalysts face a narrower runway.